ABL-IN-29

CAS No. 1430719-97-3

ABL-IN-29( —— )

Catalog No. M11821 CAS No. 1430719-97-3

ABL-IN-29 is a picomolar ABL kinase inhibitor with IC50 of 0.06/0.11 nM for wt ABL and ABL T315I respectively.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
100MG Get Quote Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    ABL-IN-29
  • Note
    Research use only, not for human use.
  • Brief Description
    ABL-IN-29 is a picomolar ABL kinase inhibitor with IC50 of 0.06/0.11 nM for wt ABL and ABL T315I respectively.
  • Description
    ABL-IN-29 is a picomolar ABL kinase inhibitor with IC50 of 0.06/0.11 nM for wt ABL and ABL T315I respectively.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Angiogenesis
  • Target
    Bcr-Abl
  • Recptor
    Bcr-Abl
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1430719-97-3
  • Formula Weight
    327.402
  • Molecular Formula
    C17H17N3O2S
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    ——
  • Chemical Name
    1-ethyl-3-(6-(2-methoxyphenyl)benzo[d]thiazol-2-yl)urea

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Park H, et al. J Am Chem Soc. 2013 Jun 5;135(22):8227-37.
molnova catalog
related products
  • GNF-7

    A potent and selective type-II kinase inhibitor of Bcr-Abl.

  • PPY A

    PPY A is a potent inhibitor of T315l mutant and wild-type Abl kinase (IC50 of 9 and 20 nM, respectively).PPY A also inhibits the growth of Bcr-Abl T315l mutant or wild-type Bcr-Abl genetically transformed cells.

  • Vamotinib

    Vamotinib (PF-114) is an orally active and specific tyrosine kinase inhibitor with antiproliferative and antitumour activity.Vamotinib inhibits the phosphorylation of BCR/ABL and BCR/ABL-T315I, which promotes apoptosis.